Basalt Health Company Spotlight: AI for Post-Acute Care

Basalt Health builds AI-assisted software for post-acute admissions, where a patient can be ready to leave the hospital while the next provider is still reading a faxed clinical packet. The Nashville company turns that packet into cited findings checked against a facility's own admission criteria, then leaves the decision with the clinician.

Founder and CEO Ben Hackett started Basalt in 2024 after nearly a decade building healthcare products at Accolade. Basalt now serves behavioral health, skilled nursing, long-term care, and rehabilitation teams. Its recent $20M Series A gives the company capital to expand into discharge and payer workflows while scaling across major health-system customers.

The larger signal is not that another healthcare company found a use for AI. It is that a focused workflow can create value without pretending the model should make the clinical decision. Basalt is trying to make the evidence arrive sooner, remain visible, and survive the operating reality around the bed.

About Basalt Health

Basalt Health describes its mission in four words: no patient waiting. The company starts from a practical bottleneck. Post-acute providers receive long referral packets, often by fax, and must decide whether they can safely care for the patient, satisfy payer requirements, and place the patient in an available bed.

Basalt's name reflects the design philosophy. Basalt rock forms a foundation, and the company wants admission decisions to rest on evidence pulled directly from the record. Its public principles are equally direct: evidence rather than opinion, clinician authority rather than automated judgment, and privacy across ingestion, review, and audit.

Hackett's healthcare product background helps explain the narrow entry point. The company is not asking a clinical team to begin with a blank chat window. It meets the referral inside the intake process, where staff already have a packet, local criteria, a patient waiting, and a clock that affects both care and bed capacity.

How Basalt Handles Post-Acute Admissions

Basalt's post-acute admissions platform reads faxed PDFs, scanned images, photographs, and electronic records. It checks diagnoses, medications, functional status, coverage, and other details against the facility's own criteria by unit and payer. The system surfaces red, yellow, or green findings, each linked to the source document.

That citation layer is the product's most important boundary. Basalt says it prepares the evidence while a clinician makes the admission decision. The same sourced information can then support prior authorization, concurrent reviews, and appeals, extending the workflow beyond the initial yes-or-no placement question.

Basalt's public security overview says the company signs a business associate agreement with every customer, encrypts data in transit and at rest, limits and logs access, and minimizes the protected health information shown to a reviewer. Those controls do not eliminate implementation risk, but they address the questions enterprise healthcare buyers ask before a product touches live patient records.

The Operating Evidence Behind Basalt

Basalt reports that its deployment at Lifepoint Health reduced median chart-processing time from 8.5 minutes to 1.2 minutes, an 86% decrease. The company plans implementation across 49 additional Lifepoint markets by the end of 2026.

At ScionHealth, Basalt says the platform is scaling to 62 hospitals by year-end across a network of more than 6,000 practitioners. These are company-reported results and rollout plans, not independently audited clinical outcomes. They still reveal what buyers are measuring: whether the same admissions team can reach a defensible answer faster.

Basalt has also placed clinicians and health-system operators upstream of product development through its Clinical Advisory Board. The board brings experience across care delivery, health-system innovation, payment, AI governance, and the operational gaps between acute and post-acute settings.

Culture, Team, and Hiring Momentum

Basalt's careers page describes six operating principles: customer obsession, curiosity, truth-seeking, transparency, accountability, and deep collaboration. The language matters because the product sits in a workflow where a hidden assumption can become an operational problem. A team that claims to value evidence has to make that value visible in the software.

As of September 24, 2026, Basalt listed four remote openings: Founding Account Executive / Director of Sales, Demand Generation Specialist, Staff Platform Generalist, and Staff AI Engineer. The mix reaches both sides of the scale problem. Engineering roles strengthen the product and platform, while the commercial roles build the pipeline and customer relationships required to move through enterprise healthcare procurement.

Hiring is not proof that demand will convert into durable growth. It is a map of where management expects the strain. Basalt is preparing for more integrations, more local admission criteria, more security reviews, more implementation work, and more customers that will judge the product inside a live care transition.

What Basalt Signals for Healthcare AI

Basalt reflects a useful turn in healthcare AI: away from theatrical autonomy and toward accountable acceleration. The company is not selling a machine that replaces the admission team. It is selling time, traceability, and a more structured way to inspect a messy record.

That approach creates its own standard. Every new facility brings different criteria, payer logic, intake channels, clinical populations, and risk tolerances. Basalt's durable advantage will depend on how reliably it can encode those differences while keeping citations clear and clinicians in control.

The Series A gives Basalt more room to prove that model across admissions, discharge, and payer workflows. The company now has to turn early time savings into repeatable implementation without letting the speed of expansion outrun the evidence discipline that made the product credible.